(Q35659489)

English

The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial

scientific article published on 27 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

S Al Sifri

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

A Basiounny

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

A Echtay

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

M Al Omari

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

I Harman-Boehm

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

G Kaddaha

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

K Al Tayeb

7

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

A S Mahfouz

8

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

A Al Elq

9

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

L Radican

10

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

C Ozesen

11

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

H L Katzeff

12

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

B J Musser

13

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

S Suryawanshi

14

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

C J Girman

15

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

M J Davies

16

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

S S Engel

17

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

2010 Ramadan Study Group

18

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

publication date

27 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

International Journal of Clinical Practice

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

65

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1132-1140

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Recommendations for management of diabetes during Ramadan: update 2010.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253336

27 July 2018

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253336

27 July 2018

The barrier of hypoglycemia in diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253336

27 July 2018

The place of sulfonylureas in the therapy for type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253336

27 July 2018

The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253336

27 July 2018

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253336

27 July 2018

Review of diabetes management and guidelines during Ramadan.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Undertreatment of cardiovascular risk factors among persons with diabetes in the United States

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Rates of hypoglycemia in users of sulfonylureas.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2011.02797.X

21 January 2018

Identifiers

10.1111/J.1742-1241.2011.02797.X

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35659489&oldid=1582613326"